__NUXT_JSONP__("/drugs/Bersanlimab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1987854-08-9",chebiId:b,chemicalFormula:b,definition:"A fully human IgG1 monoclonal antibody directed against intercellular adhesion molecule-1 (ICAM-1 or CD54), with potential antineoplastic activity. Bersanlimab selectively binds to the adhesion protein ICAM-1, which may result in antibody-dependent cellular cytotoxicity (ADCC), hyper-cross-linking-induced apoptosis, and a decrease in cellular proliferation of ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers.",fdaUniiCode:"MP3N1L4OR6",identifier:"C88327",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C20401"],synonyms:["BERSANLIMAB","BI-505",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FBersanlimab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Bersanlimab","","2021-10-30T13:46:56.163Z")));